Factors shown to contribute to the development of LMD from CNS metastasis include genomic alterations independent of primary tumor site in MAPK, CDH2, and SF3BI displaying significant gain-, loss- and switch-of-function mutations, respectively [27]. The gene discussed is CDH2; the disease is neoplasm.